MTOR and type 2 diabetes mellitus: The expression of matrix metalloproteinases (MMPs) and the imbalance of the phosphoryladylinositol 3-kinase (PI3K)/AKT/major target of rapamycin (mTOR) signaling pathway may both have an impact on the development of chronic diseases such as CVD, type 2 diabetes (T2D), and cancer [4,5].